A Phase I clinical trial of TFC-039 for the treatment of Type 2 diabetes
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2019
At a glance
- Drugs TFC-039 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 30 Jan 2019 According to a Sirona Biochem media release, the company is planning to meet Wanbang Biopharmaceuticals and anticipate a joint announcement on progress regarding the status of CFDA testing after the Chinese New Year.
- 28 Aug 2018 According to a Sirona Biochem media release, this trial is anticipated to begin as early as October 2018.
- 16 Jul 2018 New trial record